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Abstract
Calcium/Calmodulin Dependent Protein Kinase Type-I1 Associates with
Flightless-I to Influence its Nuclear Localization
By Matthew E. Seward, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University
Virginia Commonwealth University, April 2006
Major Advisor: Robert M. Tombes, Ph.D., Associate Professor, Department of Biology

~a~+/calmodulin-dependent
protein kinase type-11 (CaMK-11) is a SerIThr protein

kinase regulated by ca2+and Calmodulin. It is a highly conserved and broadly expressed
enzyme and has a unique structure and dynamic regulation. It has the ability to remain
active in the absence of ca2+as a result of ca2+dependent autophosphorylation. CaMKI1 phospliorylates proteins involved in neurotransmitter secretion, long term potentiation,
cytoskeletal dynamics, gene transcription, and cell motility. To support existing and
identify new intracellular roles of CaMK-11, potential binding partners were identified.
This was accomplished by transfecting and purifying "FLAGu-tagged CaMK-11's (a, PE,
Sc, and SE). CaMK-I1 associated proteins were then identified using tandem mass
spectrometry. Known binding partners were identified using this approach, including
CaMK-I1 and calmodulin, verifying the approach's validity. Additionally several
unexpected but interesting proteins were identified, including the gelsolin related actin
binding protein, Flightless-I. Fli-I is an actin binding and capping protein that also
functions as a transcriptional coactivator. The CaMK-11-Fli-I interaction was confirmed

with endogenous (un-tagged) proteins. The association and localization of Fli-I are
dependent on CaMK-11's activity state, although Fli-I is not a substrate of CaMK-11.
When CaMK-I1 is inhibited, Fli-I translocates to the nucleus. Conversely when CaMK-I1
is artificially activated using a ca2+ionophore, Fli-I returns to the cytosol. The discovery
of this reversible interaction represents a potentially new CaMK-I1 regulated pathway and
likely serves as a link between ca2+based signal transduction pathways and regulation of
the actin component of the cytoskeleton and transcription.

Introduction
CaMK-I1 Overview
The role of ca2+as a secondary messenger has long been established. A
component of intracellular ca2+signal transduction is the ~a~+/calmodulin
dependent
protein kinase type-I1 (CaMK-11) (Hudnion and Schulman, 2002b; Schulman, 1993).
CaMK-I1 is conserved throughout metazoans and expressed in a wide range of cell types.
It is encoded by four different genes (a, P, y, and 6) and is alternatively spliced to yield
more than forty isozymes. Individual isozymes varies in expression by cell type and
developmental progression and have unique localization patterns and presumably
substrates (Mayer et al., 1993; Tombes et al., 2003; Tombes and Krystal, 1997; Zhou et
al., 1995).

CaMK-I1 Structure
The CaMK-I1 holoenzyme consists of twelve subunits (six anti-parallel dimers)
which arrange themselves in a unique fashion (Gaertner et al., 2004; Hunter and
Scliulman, 2005; Kanaseki et al., 1991). From the amino terminus, each subunit has
three major domains; a catalytic and regulatory domain, a variable domain and an
association domain. The catalytic domain comprises the first 250 amino acid residues
and includes the ATP- and substrate-binding sites. The regulatory domain encodes the
autoinhibitory and calmodulin (CaM) binding regions over a 30 amino acid residue
region (Kolb et al., 1998; Schulman and Lou, 1989). The variable region of CaMK-I1
spans residues 3 15 to 345 up to 435, and is where alternative splicing occurs to generate
isozyme variability. Splice variants are denoted by the Greek letter of the gene that they

originate from followed by a subscripted capital letter representing the specific isozyme.
The C-terminal association domain is required for the oligomerization of CaMK-I1
monomers into dodecamers which is essential to CaMK-11's fi~nctionality.Dodecamers
can be either homomeric or a heteromeric, consisting of either entirely one isozyme or a
combination of multiple variants (Kolb et al., 1998; Lantsman and Tombes, 2005).

CaMK-I1 Activation
When the enzyme is inactive the autoinhibitory arm obstructs the active site
preventing catalytic activity. When ca2+rises, the ions are bound by the ca2+binding
protein CaM, which is then bound by CaMK-11, causing a relaxation of the inhibitory
arm, exposing the active site (Mukherji and Soderliiig, 1994; Schulman and Lou, 1989).
Partial activation of the enzyme increases its affinity for c a 2 + l c a ~raising
,
CaMK-I1
ca2+sensitivity and excitability (Meyer et al., 1992).

CaMK-I1 Autophosphorylation
In addition to its ability to form a unique and complex quarternary structure,
CaMK-I1 has the ability to autophosphorylate. The most important autophosphorylation
site is ThSS7in the regulatory domain. Autophosphorylation occurs in an intersubunit
fashion between active adjacent subunits. An activated subunit can phosphorylate ThrZs7
on another active adjacent subunit, preventing .the autoinhibitory arm from assuming its
inhibitory confirmation. This phosphorylation frees CaMK-I1 of its c ~ ' + / c ~ M
dependence allowing it to remain active in their absence because the autoinhibitory
domain is occluded from the active site regardless of their presence. This autonomy is

one of Cam-11's most interesting features because it allows the enzyme to stay active in
the absence of c a 2 + / c a ~ This
.
condition is referred to as molecular memory and makes
C a m - I 1 more dynaniically responsive to a variety of molecular conditions (Dunkley,
1992; Dupont et al., 2003; Hudmon and Schulman, 2002a; Schworer et al., 1988).

CaMK-I1 Function and Localization
CaMK-I1 gene products have been sliown to play roles in various cellular
functions and to be expressed in unique patterns. CaMK-11's role in the brain is well
established and has been shown to have regulatory roles in a number of critical neural
processes. a and p CaMK-11, for example, are regulators of neurotransmitter release
through binding and phosphorylation of synaptic targets and are functional in both the
pre- and postsynaptic densities (Benfenati et al., 1992; He et al., 2000; Yoshimura et al.,
2002). a CaMK-I1 is a regulator of long term potentiation and learning and memory
through phosphorylation of a variety of neuronal receptors including AMPA and NMDA
(Chen et al., 2001; Giese et al., 1998; Ito et al., 1991). a and P CaMK-I1 in nervous tissue
localize to a variety of regions, varying by gene, but can be found in axons, dendrites, and
cell bodies. Additional isozymes .that are expressed in the brain are encoded from tlie 6
and y genes and are found in peripheral neural tissues, such as astrocytes and glial cells
(Takaishi et al., 1992; Vallano et al., 2000). a CaMK-I1 is enriched in the frontal lobe of
the brain and both P and 6 CaMK-I1 are enriched in the cerebellum. It is not surprising
that CaMK-I1 is involved in so many processes because of its expression patterns, but
also because of its ability to respond to a variety of ca2+signals and transduce complex

signals in an efficient manner (Chang et al., 2001; Erondu and Kennedy, 1985; Li et al.,
1998).
Another well documented role of CaMK-I1 is in muscle. CaMK-I1 is expressed in
cardiac, smooth, and skeletal muscle. y CaMK-I1 has been shown to be expressed in
vascular smooth and heart niuscle. 6 isozymes regulate ca2+ levels in cardiac muscle and
are involved in the regulation of ca2+channels and the sarcoplasmic reticulum, all vital to
maintaining regular heart beat (Abraham et al., 1996; Hoch et al., 1998; Hoch et al.,
2000; Singer et al., 1997). An interesting example of CaMK-I1 in muscle is of aKAP, a
non-catalytically active form of a CAMK-I1 which is expressed in skeletal muscles and
serves as an anchoring protein (Bayer et al., 1998; Takeuchi and Fujisawa, 1997).
Developmentally, CaMK-I1 function is imperative, particularly in the brain. ca2+
transients are fundamental to successful organismal development, which makes CaMK-I1
significant to the process. 6 CaMK-I1 isozymes have been shown to be expressed
prominently during neural development (Faison et al., 2002). These isozymes are not
expressed in the adult brain and are only expressed during early neural development
(Bayer et al., 1999). Interestingly, a CaMK-11, the primary neuronal isozynie in the adult
brain is not expressed until later in brain maturation. These are prime examples of the
differential expression patterns of CaMK-I1 genes (Brocke et al., 1995; Burgin et al.,
1990).
Additionally, roles for C a m - I 1 have been documented in transcription (Enslen
and Soderling, 1994), cytoskeletal regulation (Shen et al., 1998; Takahashi, 2001), and
niorphogenesis (MassC and Kelly, 1997). It is not unanticipated that it has such a diverse
collection of functions, considering its intricate levels of regulation and unique structure.

Its behavior is dictated by both c a 2 + / c adependent
~
and autononious activity, pattern of
isozyme expression, and homo- or hetero-oligomerization, which dictate its response to
various types of ca2+signals. Its capability to discern between ca2+signal intensity,
frequency, and duration and then transduce it enzymatically give CaMK-I1 a unique
ability among protein kinases (Hudmon and Schulman, 2002b; Schulman et al., 1992).
Although much information has been established on the role of CaMK-11, many
of its substrates and binding partners have not yet been identified. Discovery of some of
these targets would yield insight into CaMK-11's purpose in the cell. One approach that
has been established as a method for identification of protein function is mass
spectrometry.

Tandem Mass Spectrometry
An effective tool for identifying the complex patterns of protein-protein
interaction is tandem mass spectrometry (MSMS) (Syka et al., 2004). Tliis technique
allows for the identification of specific peptides from a complex solution. If a particular
protein is isolated from cellular lysates any proteins that are associated with it are also
captured. When these proteins are analyzed by MS/MS not only is the target protein
detectable, so are the associated proteins. This narrows the list of candidate binding
partners from the entire proteome to those detected in the analysis and yields insight into
potentially uncharacterized functions.
A tandem mass spectrometer differs from a single MS by coupling together

multiple mass analyzers to sum their measuring capabilities to create a more accurate
analysis of the sample (Busch et al., 1988). During a MSIMS analysis a sample of

proteins in solution is reduced and denatured then digested with a protease, usually
trypsin because of its efficient and consistent nature, which yields peptides of discrete
size and charge. The sample is then introduced into a microcapillary HPLC which
separates the peptide fragments by size. The fragmented peptides are then introduced into
a highly charged electric field at a very slow rate creating highly charged droplets, a
process called electrospray ionization (ESI) (Ashcroft, 2005). The droplets pass through
a field of inert gas (most ofteii He) wliere they are disrupted by the collisioi~swith the gas
molecules causing the solution to evaporate and the peptides to further fragment, at which
point they enter illto an ion trap. A quadrupole ion trap captures peptides based on mass
to charge ( d z ) ratio by establishing discrete gradients of charge, which suspends the
peptides in space in distinct ndz ranges by electrically focusing them. Slowly each m/z
group is released by a shift of the charge gradient in the trap and the peptides are released
toward the detector, an electron multiplier (March and Todd, 2005). The detector
analyzes each peptide it sei~sesand compiles a spectrum of the peptides. The scan is
repeated, then the ten most abundant ions are selected and the cycle parameters are
altered to screen the next ten most frequently appearing peptides. The scanning
parameters are continuously redefined so only a small subset of the sample is being
analyzed at any given time. This approach ensures the most accurate assessment of the
proteins in the sample.
A computer program called SEQUEST is used to analyze the experimental
peptide sequences by comparing them to theoretical MSIMS spectra. The comparison is
made to a database that contains hypothetical peptide sequences that could be created by
protease digestion of every known protein, had they been digested in a manner similar to

how the samples were prepared. The peptides in the database are assigned a score that is
representative of the likelihood of each occurring based on the theoretical digestion. The
score of each theoretical peptide is compared to the actual MS results to establish the
validity of the data and from the analysis of the peptides a list of proteins is generated
(Hernandez et al., 2006; Yates et al., 1995).

CaMK-I1 Binding Partner Screen
An MS/MS based screen for CaMK-I1 binding partners was undertaken. In order

to partially purify CaMK-I1 from whole cell lysates, the " F L A G epitope system was
used. FLAG is an eight amino acid residue epitope tag (DYKDDDK) which allows for
efficient immunopurification of tagged proteins. The benefit of the FLAG system is that
FLAG-tagged proteins can be easily eluted from anti-FLAG antibodies in a nondenaturing manner using a FLAG-peptide. The small peptide effectively disrupts the
interaction between the FLAG tag and immobilized anti-FLAG IgG. The FLAG
antibody is conjugated to agarose beads, which when stringently washed eliminates any
non-specifically bound proteins leaving only FLAG-tagged CaMK-I1 and associated
proteins. The FLAG elution approach adequately prepares samples suitable for MS/MS
(Einhauer and Jungbauer, 200 1).
For the binding partner screen, five FLAG-rnEGFP1CaMK-I1 (a, PE, ?jC, and full
length and C-terminal tiE) fusion vectors were constructed and transfected into either NIH
3T3 cells or into P19 neurons. NIH 3T3 cells are a well established mouse embryonic
fibroblast cell line that is non-transformed, diploid, highly contact inhibited, and very
transfectable (Copeland and Cooper, 1979; Jainchill et al., 1969). NIH 3T3 cells express

CaMK-I1 endogenously, although primarily

tjc. The P19 cell line is a diploid mouse

embryonal carcinoma that can be induced to form neurons by treatment with retinoic acid
(McBurney et al., 1982). P19 neurons express at least three different

P and 6 CaMK-I1

isozymes (Johnson et al., 2000). The transfected cells were harvested, and the FLAG
tagged fusion proteins were immunopurified, eluted, and subjected to MSIMS analysis.

Experimental Approach

The CaMK-I1 binding partner screen generated a list of proteins which could be
potential CaMK-I1 binding partners. It included a number of predicted proteins given
CaMK-11's reported functions and previously established binding partners, in addition to
a variety of unique and unanticipated proteins.
One such unforeseen candidate was the gelsolin related actin binding protein
(GRABP) Fligl~tless-I(Fli-I). Fli-I was first identified in Drosophila melanogaster, in
mutant flies that had lost the ability to fly, but has been shown to have homologs in all
metazoans. It is a developmentally essential actin binding and capping protein wit11
transcriptional coactivity (Archer et al., 2005; Lee et al., 2004). This was a result that
raised particular interest given the documented role that CaMK-I1 plays in regulation of
the actin component of the cytoskeleton.
The interaction between Fli-I and CaMK-I1 was pursued for this project. It has
been speculated that Fli-I may serve as a link between several cellular pathways,
including signal transduction pathways and regulation of the cytoskeleton through a yet
to be identified protein (Davy et al., 2000; Fong and de Couet, 1999). It was hoped that it
could be shown that CaMK-I1 is a factor in this signal transduction pathway through its

interaction with Fli-I. Several questions were initially laid out to guide the study,
including:
Do endogenous CaMK-I1 and Fli-I interact?
What is the nature of their interaction relative to CaMK-I1 activity?
Does C a m - I 1 activity affect the localization of Fli-I?
To answer these questions a number of approaches were taken. Antibodies
against Fli-I and CaMK-I1 made it possible to confirm the interaction through reciprocal
immunoprecipitations of endogenous proteins and also to perform immunolocalization
experiments. Using different classes of CaMK-I1 inhibitors, media conditions, and
constitutively active CaMK-I1 constructs I have characterized the nature of the Cam-11Fli-I association. I have also found that CaMK-I1 and Fli-I interact in a manner
dependent on CaMK-I1 activity which also affects Fli-1's cellular localization.

Methods

NIH 3T3 Cell Culture.
NIH 3T3 cells were maintained in DMEM with 10% FBS, L-Glutamine,
Penicillin, and Streptomycin at 37OC in a 5% C 0 2 incubator in plastic tissue culture
dishes (Nunc, Rochester, NY). Serum free experiments were in DMEM
(Gibco/Invitrogen, Carlsbad, CA) with 0% FBS, L-Glutamine, Penicillin, and
Streptomycin.

PI9 Embryonal Carcinoma Cell Culture.
Undifferentiated P19 cells were maintained in 10% FBS, L-Glutamine, Penicillin,
and Streptomycin at 37OC in a 5% C 0 2 incubator. They were induced to differentiate by
treatment with 5x10-'M all trans retinoic acid (ATRA) at 1x1o5 cells/ml in DMEM, 5%
FBS, in bacteriological petri dishes for 4 days. The induced cells formed embryoid
bodies, which were then plated at 2-5 x lo5 cells/cm2 on tissue culture dishes. Dishes
were pre-coated with EHS laminin (0.1-0.5 pg/ml) in neurobasal medium containing N2
supplement (Invitrogen) on day 0.

Drug Treatment.
The CaMK-I1 inhibitors, KN-93 and mAIP were used at a final concentration of
10 pM and were added directly to cell cultures. The ca2+ionophore, ionomycin was used
at a final concentration of 1 pM. It was prepared as 1mL of 2 pM stock in serum free
media then added to 1 mL of cells in culture.

Cell Harvest.

Cells were harvested by trypsin-EDTA and resuspended in Homogenization
buffer with 30mM 4-(2-Hydroxyethy) piperazine-1-ethansulfonicacid (HEPES, pH 7.4),
2.6 mM EGTA, 20mM MgC12, 80mM eglycerol phosphate, 0.1 pM okadaic acid, and
10 pg/mL of chymostatin, leupeptin, aprotinin, pepstatin, and soy bean trypsiii inhibitor.
The cells were sonciated on ice with two five seconds burst from a probe sonicator
(Misonix, Farmingdale NY) and centrifuged at 4OC for 15 minutes at 12,000 x g. Protein
concentrations were quantitated in triplicate with the BCA protein assays (Pierce,
Rockford, IL) then immediately aliquoted and frozen at -80°C.

FLAG-tag Fusion Vector Construction.

The four full length CaMK-I1 isozymes in this study (a, PE, &, and &) had been
previously cloned into the EGFP-C 1 vector (Clontech) as well as a C-terminal&
construct, which is a truncated construct lacking the first 308 amino acid residues, the
sequence that codes for the catalytic domain. The GFP sequence had a point mutation to
prevent the dimerization of GFP, by changing ~ e u ~to "a

Monomeric EGFP

(inEGFP) tagged CaMK-I1 sequences were amplified through PCR, using Hi-Fidelity
Platinum Tag polymerase (Invitrogen). The amplification was primed at the C-terminal
end of the gene, with a primer containg a BamHI cut site. The a and P were specifically
primed by, CCCGGATCCTTACTGGGGCAGGACGGAGG and
CCCGGATCCTCACTGCAGCGGGGCCACA, respectively. The three 6 constructs
were primed with a y specific primer because each was a chimera with the y association
domain with the primer CCCGGATCCTCACTGCAGCGGTGCGGCA. The N-terminal

side of the GFP sequence of all five constructs was targeted by a primer with a KpnI cut
site, CGCGGTACCATGGTGAGCAAGGGCGAGGAG. The PCR products were
ligated into the pCDNA-3.1' vector, which had previously had the FLAG-2AB sequence
cloned into it at the Hind111 site of its multiple cloning region (the plasmid was provided
courtesy of Dr. Mark Mayhew at the University of Virginia). Five vectors were created;
FLAGImGaWT, FLAGImGPWT, FLAG/mGGcWT, FLAG/mGGEWT,and FLAG/mGGEC-terminal. The constitutively active FLAG construct (FLAG/mGGECon)was generated
by site directed mutagenesis, substituting ~s~~~~for ~

h of arFLAG/mGGEWT
~
~
~

construct (GCATCGTCAGGAGGACGTGGAGTGTTTGCG) using Pfu Ultra high
fidelity long read polymerase (Stratagene, LaJolla, CA). The plasmids were confirmed
by restriction digest, immunoblots, CaMK-I1 activity assays, and DNA sequencing and
showed tliat all five had been accurately constructed.

FLAG-transfection.
Approximately 80% confluent cells in 1OOmm tissue culture dishes were
transfected with 4 pg of FLAG plasmid and diluted with 8pg of p

~

~using
- ~

~

lipofectamine 2000 in Optim-MEM and 3% FBS (Invitrogen, Carlsbad, CA). Four hours
post-transfection, cells were either refed with DMEM/lO%FBS or trypsinized and
replated at 50% of their original confluence in DMEM/lO%FBS. Cells were harvested
18-24 hours later as described above.

+

FLAG Immunoprecipitations.
1 mg of total protein from FLAG-transfected cell lysate was precleared with 50pL
of mouse IgG conjugated to agarose at lmg/mL (Sigma, St. Louis, MO) overniglit at 4OC
with rocking. The supernatant was then combined with 50uL M2 agarose anti-FLAG at
O.Gmg/mL (Sigma) and incubated for 2-5 hours with rocking at 4OC. The beads were
then washed twice with 0.5mL HBIprotease and phosphatase inhibitors/O.l%NP-40,
followed by one wash with 0.5 mL of sterile 30mM Tris pH 7.4. Immunoprecipitated
proteins were then eluted twice with 100 pL sterile 30mM Tris and 0.2 mg/mL FLAGelution peptide (Sigma) for 15 minutes on ice. Samples were immediately frozen until
M S M S analysis.

Tandem Mass Spectrometry.

Samples for MS/MS were prepared by reduction and alkylation. A portion of the
FLAG eluent was incubated in 10 mM DTT for 1 hour at 37OC to reduce the sample then
alkylated, with 5 pM Iodoacetic acid for 30 minutes at room temperature in the dark and
then again with DTT to quench the Iodoacetic acid. The sample was then digested with
Endoproteinase Lys-C, which cleaves peptides on the C-terminal side of Lys residues,
and Trypsin, which cleaves at the C-terminal side of Arg and Lys residues, at 200 pg/mL
for one hour at 37OC. The mass spectral analysis was performed on a Finnigan LTQFTMS machine and analyzed using tlie accompanying software and scored using the
SEQUEST approach (ThermoElectron Corp, San Jose, CA). These protocols are the
standard teclmiques used at the University of Virginia Mass Spectrometry Facility and
can be found in greater detail at:

Immunoprecipitations.

100 pg of NIH 3T3 lysate protein was incubated with 1 pg of primary antibody
overnight at 4OC. 1.5 pg biotinyalated secondary antibodies were added to the solution
and incubated for 2 to 5 hours at 4OC. They were then incubated with 30 pL of prewashed streptavidin-Magnesphere (Promega, Madison WI) or Protein-G Dynabead
(Dynal/Invitrogen, Carlsbad, CA) paramagnetic beads for 1-2 hours at 4OC with rocking.
The Immunoprecipitates were then washed 3 times with 500 pL cold HB in a magnetic
separation stand and were then resuspended in 20 pL of HB. Immunoprecipitates for
CaMK-I1 activity assays were frozen until use or were combined with SDS sample buffer
containing 30 mM DTT and boiled for SDS-PAGE.

Immunoblots.

Immunoprecipitates were separated on 4-15% or 10% SDS-PAGE gels using the
Mini-Protean I1 gel electrophoresis system (Bio-Rad, Hercules CA). Proteins were
transferred to 0.45 pm nitrocellulose sheets for 1 h at lOOV and blocked with Tris
Buffered Saline, 0.01% Tris-20, and Sodium Azide (TBSTA), containing 5% BSA and
2% pre-immune serum of the secondary antibody host for 1 hour. Blots were then
incubated overnight with primary antibodies at 1 pg/ml in 2% BSAITBSTA. Blots were
washed three times with TBSTA and incubated for 2-5 hours with alkaline phosphataseconjugated secondary IgG at 2 pglml in 2% BSAJTBSTA. The blots were washed once in

O.1M NaCl and 5mM MgC12 at pH 9.4 and developed with 0.25 mg/niL of both nitro blue
tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP).

Total Protein Stain.
Saniples to be stained for total protein were separated on 10% polyacrylamide
gels. The gel was then fixed for 30 minutes at room temperature in 50% methanol and
10% acetic acid. It was then incubated overnight at room temperature in undiluted
SYPRO Ruby protein gel stain (Molecular ProbesIInvitrogen, Carlsbad, CA) in an
opaque developing tray. The gel was washed twice for thirty minutes in a 10% methanol
and 7% acetic acid solution then rinsed twice with dH20 and visualized on a Wtraiisilluniinator (UVP, Upland California).

Calmodulin Overlay.
The samples for calmodulin overlays were transferred to nitrocellulose, and then
blocked with TBS containing 0.1% Tween-20,2rnM CaC12 for 30 minutes at room
temperature. Blots were then placed in TBSTAl2mM CaC12 with 1pg/mL of biotinylated
calmodulin (Calbiochem, San Diego, CA) and incubated overnight at room temperature.
The blots were then washed three times in TBSl2mM CaC12/0.1% Tween-20 for 10
minutes at room temperature. Blots were then transferred to TBSl2mM CaC12/0.1%
Tween-20 and 2pgImL alkaline phosphatase-conjugated streptavidin (Jackson
Immunology Labs, West Grove, PA) and incubated at room temperature for 1-2 hours.
All blots were washed three times as above and developed in 0.25 mg1mL of NBT and
BCIP each in O.1M NaCl and 5niM MgC12 at pH 9.4.

CaMK-I1 Activity Assays.
Total CaMK-I1 activity was assessed by measuring phosphate incorporation into
an artificial substrate. The kinase reactions were carried out in a solution of 20 mM
HEPES (pH 7.4), 0.1 mM dithiothreitol, 15 mM magnesium acetate, 20 mM Pglycerophosphate, 0.5 pM PKA inhibitor peptide, 0.1 pM okadaic acid, 40 pM sodium
~ ~pM
~ ]autocamtide-2
,
(peptide substrate), 1 pM
orthovanadate, 0.5 mCi [ y - 3 2 ~ - 35
calmodulin, 1 mM EGTA, and either none or 3 mM ca2+.The reaction ran for 10 minutes
at 30°C, then 20 pl was pipetted onto P81 phosphocellulose paper squares that were air
dried for 1 mi11 and washed five times in 500 mL 1% phosphoric acid. The samples were
quantitated by Cerenkhov counting in a Beckman LS6000IC scintillation counter. The
sequence of autocamtide-2 is KKALRRQETVDAL and the assay conditions were
previously optimized for detection of CaMK-I1 activity ( Tombes et al., 1999; Tombes et
al., 1995).

Imunolocalization.
Cells were grown on glass cover slips that had been preincubated with 1 pg/mL of
fibronectin and then fixed in methanol at - 2 0 ' ~for 3 min. Fixed cells were blocked
overnight at 4OC in TBSTA containing 5% BSA and 2% appropriate pre-immune serum.
Cells were then incubated for 1 hour at 37OC with 0.2 yg/mL of primary antibody in
TBSTA/2% BSA in a humidified chamber solution then washed in TBSTA three times
for 5 minutes. The cover slips were then incubated with 1 pg/mL of Texas Red
conjugated secondary antibody in TBSTA/2% BSA for 30 minutes at 37OC in a

humidified chamber and washed as described above. They were then mounted onto glass
slides and stored until imaged.

Imaging.

All phase contrast and fluorescent images were taken 011 an Olympus IX-70
inverted microscope using a 12-bit camera (Olympus, Melville, NY). Fluorescent images
were taken with two second exposures using a 595 nm dichroic long pass filter (Chroma,
Rockingham, VT) illuminated by a mercury arc lamp. The images were processed using
Olympus Microsuite version Five.

Antibodies.

The mouse anti-flightless-I antibody was a purified moi~oclonal,mouse IgG, at
ImgImL, from Covance, Berkeley, CA. The mouse anti-p CaMK-I1 primary antibody
was obtained from ZymedIInvitrogen Carlsbad, CA. The goat anti-6 CaMK-11, rabbit
anti-GFP and goat anti-Tropomodulin-3 were purchased from Santa Cruz
Biotechnnology, Santa Cruz CA. The monoclonal mouse anti-cofilin and anti-integrin
was bought from BD Biosciences/Pharmingen in Sane Diego, CA. The goat anti-mouse,
texas red conjugated, donkey anti-mouse conjugated to biotin, donkey anti-goat biotin
conjugated, and biotinylated donkey anti-rabbit secondary antibodies were all purchased
from Jackson Imunological Laboratories, West Grove, PA.

Results

Identification of CaMK-I1 Binding Partners.
The first half of this study was to identify protein binding partners of CaMK-I1
using M S N S . Five FLAG-tagged CaMK-I1 (a, PE, i?iC, tiE,and i?iE C-terminal) constructs
were transfected into NIH 3T3 cells and one into P19 neurons. The bait DNA was
diluted 1:3 with an empty pBlueScript vector, which kept the transfection efficiency high
but allowed for the tagged CaMK-I1 to mix with the endogenous population. This helped
to correct for the artificial nature of the experimental conditions.
Four hours post-transfection the cells were sub-cultured to ensure that the cells
were motile and actively progressing through the cell cycle. They were harvested 16-24
hours later. The tagged proteins were isolated with antibodies against the FLAG-tag and
eluted two times using a FLAG-elution peptide. The FLAG IP and elution process
effectively cleared non-specifically bound proteins from the lysates during the first
elution, which was confirmed by total protein stains and GFP Western blots (Figures 1A
and B).
The eluents of the IPS were then analyzed by MSIMS and yielded a number of
potential binding partners. In total eleven MSIMS experiments were conducted. The
first was with the FLAG/mGGE-C-terminalconstruct, which lacked the catalytic domain
and was carried out in transfected P19 neurons. In this experiment CaM and CaMK-I1
were detected, which served as an internal control supporting the validity of the
approach. Additionally several previously identified CaMK-I1 binding partners were
detected including btubulin and P- and y-actin fbrther corroborating the legitimacy of

the data (Easley, et al., 2006). Experiments two and three were duplicate experiments of
each other with FLAG/mGPEWT. The results from the experiments were nearly
identical, further substantiating the results as authentic. The fourth, fifth, and sixth
experiments were performed in the same fashion as the initial three, except with
FLAGImG ScWT, FLAGImG FEWT, and FLAGImGDaWT, respectively. The PE, SCand
SE isozymes were selected because they are all endogenously expressed in NIH 3T3 cells.
a CaMK-I1 is not typically present, but it represented an effective point of comparison, as

did SE-C-terminal because it is effectively catalytically inactive which is why they were
chosen for the screen.
The results from these six experiments yielded many previously unidentified
binding partners including a number of actin capping and binding partners, such as Fli-I
(and two of its associated proteins LRRFIP-I and -II), tropomodulin-3, and cofilin.
These actin capping proteins were of particular interest because of the documented but
not specifically characterized role of CaMK-I1 in cytoskeletal regulation. Other proteins
of interest identified in the screen included myosin heavy and light chain and vimentin
(table I).
Four additional M S M S experiments were performed using less stringent
harvesting and immunoprecipitating conditions. Low salt HB, which was similar to the
composition of standard HB except for the lack of 80 mM P-glycerol phosphate, was
used to reduce the ionic strength of the buffer. FLAG/ FE-C-terminal and
FLAG/mGSEWT were transfected into NIH 3T3 cells and harvested under both normal
and low salt coiiditions and analyzed by MSMS. Although it was suspected that
additional proteins could be identified because their interaction with CaMK-I1 had been

disrupted by the stringency of the preceding experiments, no additional candidates were
detected by this method. The final experiment was a negative control experiment using
FLAGIGFP with no cDNA cloned into it and harvested under the standard conditions.
The results from this experiments were subtracted from the data to correct for proteins
that may have non-specifically bound either GFP or the FLAG-tag.
A large volume of data was generated from the various MSIMS experiments. It
was not possible to initially pursue all of the potential binding partners identified in the
screen. It was necessary to select either one or several specific targets to characterize
experimentally. Additionally, several pieces of the data were dismissed as artifacts of the
experimental conditions. These included peptides corresponding to human keratins that
were detected in all of the screens because they were assumed to be contamination that
was introduced during the preparation of the samples. Other results were generated by
only one or two peptides and were given a very low score of legitimacy and were also
dismissed. Certain results, such as various immunoglobins and several stress response
proteins were disregarded as false positives. A list of all of the identified proteins can be
found at littp://www.cellmigration.org/resource/discoveryl#binding.
A review of the current literature made Fli-I the first choice for detailed analysis
from our screen. The interaction of CaMK-I1 and Fli-I had the most potential for further
analysis. The commercial availability of a quality antibody against this protein helped to
establish it as the subsequent focus of the study.

Interaction of Endogenous Fli-I and CaMK-11.
The identification of Fli-I as a potential CaMK-I1 binding partner from our
MSIMS screen was in an artificial system due to transfection and the over expression of
CaMK-11. It was essential to confirm this as a legitimate interaction and not an artifact of
the experimental conditions. This was done by using reciprocal immunoprecipitations of
untreated NIH 3T3 lysates.
When P and 6 CaMK-I1 antibodies were used to immunoprecipitate endogellous
proteins it was possible to successfully probe for Fli-I on Western immunoblots. Both
IPS yielded a band in the 145kDa region which corresponds to the MI of Fli-I (Figure
3A). Although a CaMK-I1 was used in the M S N S screen it is not normally expressed in
NIH 3T3 cells, so it was not possible to test this endogenous interaction.
Conversely, Fli-I was immunoprecipitated from untreated 3T3 lysates. The
immunoprecipitate was transferred and probed with CaM to screen for CaM binding
proteins. For this purpose this approach is more effective than a traditional immunoblot.
Many CaMK-I1 isozymes have a similar MI as IgG heavy chain and so they migrate at
similar rates during SDS-PAGE experiments. It is not possible to discern whether the
bands that are detected because the secondary antibody is bound to the IgG heavy chain
or to CaMK-11. Using CaM conjugated to biotin makes it possible to eliminate off-target
interactions of the secondary antibody and to screen only for CaM binding proteins. As
was expected the CaM overlay experiment revealed bands in the 50-60 kDa region,
which corresponds to CaMK-I1 isozyme migration patterns (Figure 2B).
Additionally we used Fli-I IPS to screen for associated CaMK-I1 with CaMK-I1
enzymatic activity assays. Using autocamtide-2, an artificial CaMK-I1 substrate it was

possible to detect CaMK-I1 enzymatic activity by measuring the incorporation of 3

2 ~

from Fli-I IPS into the peptide. Kinase reactions run with this IP showed -thatalmost 20%
of the CaMK-I1 activity detected in whole cell lysates could be recovered in the IP. This
is in comparison to immunoprecipitation with an anti-integrin antibody, which is a
protein known to not bind CaMK-11, in which only 1% of the total cellular activity could
be recovered. This experiment confirmed the interaction enymatically (Figure 3C).

CaMK-I1 Activity Dependent Interaction with FIi-I.
The next question I raised explored the nature of the CaMK-11-Fli-I interaction in
relation to CaMK-I1 activity. For this, NIH 3T3 cells were transfected with FLAG/mGGE
constructs and the level of CaMK-I1 activity was varied. Several approaches were
utilized to vary CaMK-I1 activity; one was to use a constit~~tively
active CaMK-I1 mutant
(FLAG/mG&Con), which had an ~s~~~~point mutant at ~ h r ~ "the
, autophosphorylation
site. The other cells were transfected with wild type constructs (FLAG/mGGEWT). To
inhibit CaMK-I1 we used two different drugs, KN-93 a reversible CaM antagonist which
prevents CaM binding and hence CaMK-I1 activation and a myristoylated autoinhibitory
peptide (rnAIP), a membrane permeant peptide which mimics the autoinhibitory domain
of CaMK-11, inactivating CaMK-11. The lysates of the transfected cells were
immunoprecipitated with an antibody against the GFP tag and then probed with Fli-I
antibodies. The constitutively active CaMK-I1 co-precipitated a much greater amount of
Fli-I than did the untreated wild-type CaMK-I1 suggesting that the increased level of
activity resulted in a greater degree of association. Conversely, the KN-93 and mAIP
inhibited lysates immunoprecipitated less Fli-I than the wild type sample and

considerably less than the constitutively active sample (figure 4A). Interestingly, when
the samples were immunoblotted for GFP as a control, the FLAG/mGGECon was
expressed at a lower level that then other samples (not shown). Additionally, when the
total CaMK-I1 activity in the samples was measured as a means of determining the
relative concentration of CaMK-I1 it was seen that the inhibited C a m - I 1 samples were
expressed at 5 times the levels of the wild type and twenty times the level of the
constitutively active sample (figure 4B). This is consistent with what is normally seen;
the constitutively active CaMK-I1 is expressed at lower levels, although the exact cause
of this phenomenon is unknown. The percent of CaMK-I1 autonomy in the samples was
determined enzymatically. It revealed that over 50% of the CaMK-I1 in the constitutively
active sample was autonomous as compared to less than 20% in the untreated sample and
no more than 2% in the inhibited samples (figure 4C). These three results create an
interesting picture in which the CaMK-I1 in the constitutively active sample, although
expressed at a lower level bound more Fli-I than did the inhibited samples, which were
expressed at greater levels. The activation state of CaMK-I1 dictates whether it is capable
of binding Fli-I.

Localization of Fli-I in NIH 3T3 Cells.
The confirmation of the interaction between CaMK-I1 and Fli-I in untransfected
cells and the dose dependent interaction in transfected cells raised questions about the
patterns of Fli-I localization in vivo. This was addressed by immunohistochemistry using
Fli-I antibodies. NIH 3T3 cells were grown on glass coverslips then fixed in methanol.

Methanol rather than formaldehyde was the fixative used because the latter caused a loss
of Fli-I antigenicity.
We observed that in untreated cells there are several distinct localization patterns.
Fli-I is capable of nuclear translocation under certain conditions and was found in many
cells (Figure 5A), but in many of the cells in the same sample it localized outside of the
nucleus. This is consistent with published results on Fli-I localization patterns. It is
believed that when Fli-I is located in the cytosol it is associating with actin based
structures, such as those found at the leading edge of motile cells and in perinuclear
regions (Figures 4B and C). The patterns observed in the experiments are consistent with
the current models of Fli-I behavior. Fli-I is known to act as a transcriptional co-activator
and nuclear receptor binding protein, both of which may be coupled to its nuclear
translocation, but it is believed that this translocation occurs primarily when cells are cellcycle arrested or non-motile. Although it was observed that Fli-I could assume one of
several localization patterns, groups of neighboring cells seemed to generally exhibit
similar patterns, which is likely the result of the cells responding to cues in their
microenvironment which influence their behavior.

Fli-I Localizes to the Nucleus in Arrested Cells.
Since within a single culture Fli-I could assume one of several localization
patterns it was a challenge to create a consistent trend throughout each experiment.
Based on published findings that Fli-I is sequestered in the nucleus of arrested cells, it
seemed logical that arresting the cells via serum deprivation would syiichronize the entire
population of cells in each experiment. With this treatment it was possible to induce

arrest throughout the culture, which caused the cells to display only nuclear localization
patterns (Figure 6B and C). This induced arrest allowed more direct control of the cells'
progression through the cell cycle and their migratory state. It was also realized that
greater regulation could be established if the cells were plated on glass coverslips that had
been pre-incubated with fibronectin (FN). This allowed the cells to attach at a faster rate
so it was possible to more directly regulate the cell density. The density of the culture
was important because the cells are inhibited by contact and will readily arrest when they
touch neighboring cell and cause Fli-I to translocate to the nucleus (Figure 6D).

Fli-I Does Not Localize to the Nucleus in Serum Stimulated Cells.

It was necessary to accurately characterize the behavior of Fli-I under various
conditions before being able to assess the effects of CaMK-I1 activity on its localization.
Serum starving cells overnight after they had been plated on FN coated coverslips was
adopted as the standard practice for all of the Fli-I localization experiments. Once the
cells had been arrested overnight, they were then released by stimulation with 10% FBS
containing medium. Cells that were fixed at various time points post-stin~ulationshowed
an increasing return of Fli-I to the leading edges of the cells. Six hours after the cells
were stimulated, Fli-I could be seen associating with actin arches throughout the cells
(Figure 7C). It seemed as although by 15-16 hours the majority of the cell's Fli-I is
extra-nuclear, with some being localized in the perinuclear region and much of it
localized to ruffles at the cell's edge (Figure 7D). Although it is possible to induce
exportation of Fli-I from the nucleus of arrested cells by stimulating, we still observed
that once the cells begin to contact one another it induced Fli-1's return to the nucleus,

meaning that the contact induced arrest is able to overcome the effects caused by the
serum stimulation.

CaMK-I1 Inhibition Also Targets Fli-I to the Nucleus.
It was apparent from the initial localization experiments that Fli-I is a very
dynamic molecule and that its localization is closely coupled to the activity state of the
cell. Once protocols had been established for regulating Fli-1's behavior as consistently
as possible, it was feasible to determine the effects of CaMK-I1 activity on its
localization. The first goal was to limit CaMK-I1 activity and assess the effects on Fli-I
localization. This was accomplished with the CaMK-I1 inhibitor KN-93. The cells were
plated in the same fashion as they were in the serum dependence experiments, but 10 pM
KN-93 was added to the media at the same time point that serum free medium has
previously been added. In a very similar manner to serum starvation, KN-93 caused Fli-I
to shuttle into the nucleus. This effect was observed in a time dependent fashion with the
the effect being seen within four liours (figure 8B), continuing to translocate in at 12
hours (figure 8C), and being all in by 18 hours (figure 8D). A similar experiment was
performed using 10 pM mAIP as the CaMK-I1 inhibiting agent. This treatment resulted
in an effect very similar to the KN-93 dependent inhibition. The mAIP caused Fli-I to
exit the cytoplasm of the cells and migrate to the nucleus within 90 minutes (Figure 9B)
and being non-cytosloic by three hours (figure 9C). The mAIP had maximal effect
within three hours, which was much faster than what was seen with the KN-93 treatment,
but this is likely due to the differences in the two drugs' specific modes of action. It was
very interesting to be able to induce Fli-I localization patterns similar to those seen in

arrested cells by inhibiting CaMK-11. This complemented the Fli-I Western blot of the
various CaMK-I1 activity treatments in an in vivo model.

Fli-I Leaves the Nucleus in Artificially Activated CaMK-I1 Cells.
Once it was clear that Fli-I could be sequestered to the nucleus by restricting
CaMK-I1 activity, I wondered if I could reverse this localization by artificially activating
CaMK-11. The first thought was to transfect cells with a constitutively active CaMK-I1
and localize Fli-I, which was the most straight forward approach to forcing Fli-I to return
to the cytosol. Although we were able to successfully transfect the cells, there was no
noticeable effect on Fli-I localization. It was observed however, that cells that had been
transfected with the constitutively active construct had arrested, which resulted in Fli-I
assuming nuclear localization. It was unclear if this effect was the result of the CaMK-I1
activity or another pathway, but it was apparent that it would not be an effective effective
for demonstrating the effect of C a m - I 1 activity of Fli-I localization. The next method
employed was to artificially activate endogenous CaMK-I1 by treating cells with the ca2+
ionophore ionomycin. Ionomycin causes ca2' influx into cells, which results in CaMK-I1
activation. The cells were maintained in serum free media, which we had previously
shown to cause Fli-I to transport to the nucleus. Although the culture was maintained in
the absence of serum, treatment with ionomycin caused Fli-I to exit the nucleus and
associate with stress fibers and in the perinuclear region of the cell. The transport of Fli-I
out of the nucleus occurred in a time dependent fashion, with the effects becoming
noticeable between 3 to 6 hours post-treatment (figure IOB) and seemingly complete by
16 hours (figure 10C) after the drug was added. When compared to the effects seen when

cells are treated with serum free media, the translocation of Fli-I in response to ca2+
establishes a clear link between it and cellular ca2+and when combined with the results
of CaMK-I1 inhibition it confirms that CaMK-I1 serves as a regulator of Fli-I.

Discussion

The role that CaMK-I1 plays in essential cellular functions is often
underappreciated. Its high level of evolutionary conservation, broad patterns of
expression, and unique regulation exemplify the essential role of CaMK-I1 in cellular
function (Tombes et al., 2003). To identify new functions of the protein it is necessary to
use open minded approaches. An unbiased process for achieving this goal is to discover
new binding partners in the hope that they could be correlated to unknown functions.
The MSIMS used in study was ideal for this type of screen.
The MSIMS screen is an excellent tool for the identification of binding partners,
although the artificial nature of the system made it susceptible to erroneous results.
Although false positive results were a possibility the identification of both CaM and
CaMK-I1 in the screen validated the methodology. Although the data appeared genuine it
was necessary to confirm the endogenous interaction. In particular Fli-I was a fascinating
result and it had a commercially available high quality antibody against it, so it was the
logical choice for study. Several additional targets were considered including
tropomodulin-3 and cofilin, but the antibodies purchased against these proteins could not
be confirmed as efficient in endogenous systems so they were not pursued further (data
not shown).
Fli-I is a member of the Gelsolin Related Actin Binding Partner (GRABP) family.
It is a 145 kDa protein that is highly conserved and expressed in all metazoans. The Cterminal side of Fli-I is a Gelsolin-like domain which gives Fli-I its actin binding and
capping ability and the N-terminal half is a Leucine Rich Repeat (LRR), a conserved

domain known to be involved in protein protein interactions (Archer et al., 2005;
Campbell et al., 2000). The gene was identified in Drosophila melanogaster mutants that
did not develop the ability to fly. It was discovered that they were lieterozygous mutants
of the gene located on the 19F region of the X-chromosome and that the loss of flight was
the result of a failure to successfully cross bridge the actin filaments of in-direct flight
muscles. Homozygous Fli-I null mutants are embryonic lethal, which is a more severe
phenotype than villin or double Cap-G and Gelsolin knockouts, both GRABPs family
members. The lethality of the knockouts and the high degree of genetic conservation are
illustrative of the importance of this niolecule (Lee et al., 2004; Straub et al., 1996;
Campbell et al., 2002).
Fli-I possesses a variety of functions. It is known to have actin binding function
and to associate with actin based structures during development and cell motility (Davy
et al., 2000; Davy et al., 2001). Additionally, Fli-I fuiictions as a transcriptional coactivator through its interactions with nuclear receptor based complexes as identified
during yeast-two hybrid screens (Archer et al., 2004; Lee et al., 2004; Liu and Yin, 1998;
Archer et al., 2005). This broad range of functions is apparent by the intra- and
extranuclear localization patterns it exhibits.
Fli-I lacks a domain that would allow it to respond to ca2+,which is something
that the other members of the GRABP family possess (Fong and de Couet, 1999). ca2+
based signaling is fundamental to many cellular processes including regulation of
cytoskeletal dynamics. Fli-I is a critical component of this process and although it is not
directly regulated by ca2+transients it could be controlled by them through its interaction
with CaMK-11. It has been speculated that Fli-I could serve as an intermediate between

ca2+based signal transduction pathways and the regulation of cytoskeletal dynamics
(Claudianos and Campbell, 1995; Davy et al., 2000; Davy et al., 2001).
The Fli-I antibody was specific in immunoblots of endogenous 3T3 and P19
lysates. This made it possible to probe for its presence in CaMK-I1 IPS and also to screen
for CaM-I1 in Fli-I IPS. The CaMK-I1 IPS contained Fli-I on Immunoblots, which
verified the interaction and was supported by the detection of CaMK-I1 in Fli-I IPS, both
immunologically and enzymatically. The complementary nature of these experiments
which were performed on native proteins corrected for the synthetic nature of the initial
screens. The reciprocal verification of the interaction confirmed the legitimacy of the
MS/MS result.
The authenticity of the interaction was apparent and seemed to have potential as
molecularly significant, but nothing was known of the nature of the interaction. All of
the M S M S experiments contained Fli-I so it was not possible to discern any information
from the variations in the screens. Since CaM-I1 fbnction is closely coupled to its
activation state, it was logical to wonder if that had an effect on the association.
Transfection of NIH 3T3 cells with GFP-tagged constructs offered several
advantages in charactering the CaMK-11-Fli-I association. It made it possible to use a
constitutively active variant and to immunoprecipitate against the GFP-tag whicli is more
specific than antibodies against CaMK-11. The inhibited samples were also transfected to
maintain consistency between the samples. These experiments illustrated the activity
dependence of the interaction. The increased quantity of Fli-I bound to constitutively
active CaMK-I1 and decreased association as a result of lowered activity suggest that the
nature of the interaction makes it possible to determine the activation state of CaMK-11.

Little is currently known about the domains that are facilitating the interaction of
these proteins, but it is clear that the activation state of CaMK-I1 somehow regulates the
interaction. A likely possibility is that upon CaMK-I1 activation a Fli-I binding site is
either created or exposed. Recent work on the crystal structure of CaMK-I1 suggests that
activation causes the core domain of the CaMK-I1 holoenzyme to expand, which could
expose a Fli-I binding site (GaeiZner et al., 2004; Rosenberg et al., 2005). Fli-I possesses
a traditional nuclear localization signal (PKKKRKV). It is possible that when Fli-I is
b o ~ ~ ntodCaMK-I1 the sequence is obstructed, preventing the formation of a nuclear
import complex. Although CaMK-I1 activation occludes Fli-I from the nucleus, the
isozymes of CaMK-I1 examined in this study are non-nuclear, so they can not enter the
nucleus to retrieve Fli-I. An explanation is that CaMK-I1 is not responsible for Fli-1's
export from the nucleus, but maintains its presence in the cytosol when it is active.
Fli-I is very active in its localization. Since it becomes sequestered to the nucleus
of arrested cells, it made sense that the translocation could be correlated to its association
with CaMK-11. Localizing Fli-I in control cultures proved to be a challenging task. To
accomplish this it was necessary to synchronize the progression of the cell's cycles and to
closely control their density. This was achieved by arresting and releasing them and
culturing them on FN. Much information about the nature of their binding became
apparent when the localization patterns of Fli-I were characterized during various cell
activity states and comparing them to multiple levels of CaMK-I1 activity. In arrested
cells Fli-I is found primarily in the nucleus and although some can be detected outside the
nucleus, it is non-specifically present. The location of Fli-I is similar in arrested cells and

CaMK-I1 inhibited cells suggesting that under naturally occurring conditions their
interaction may be somehow correlated to the cell cycle and to cytoskeletal dynamics.
It was asked if Fli-I was not only a CaMK-I1 binding partner, but also a substrate.
Phosphorylation could represent an additional level of regulation in addition to the
activity dependent binding between the two proteins. There are five potential CaMK-I1
consensus sequences in Fli-I, but the structure of the protein is unknown so they may not
actually be phosphorylatable. This was tested by partially purifying CaMK-I1 and
~ ~assay
] . was crude in
combining it with Fli-I IPS in the presence of [ y - 3 2 ~ - ~The
nature, but the initial autoradiographs indicate that Fli-I is not a CaMK-I1 substrate (data
not shown). Although the reactants were not completely pure and the results can not be
considered definitive, they are still convincing. Binding that is dependent on
autophosphorylation is a seen throughout the cell, such as receptor tyrosine kinases,
which a~~tophosphorylate
when they bind ligands to mediate their signal transduction by
only binding signaling proteins when they are phosphorylated. It is possible that CaMKI1 binds Fli-I through a similar mechanism.
A clue to the function of the interaction is another binding partner identified ill the
screen, the protein known as leucine rich repeat region of Fli-I interacting protein I1
(LRRFIP2). Little had been known of the function of LRRFJP2 other than its association
with Fli-I, until recently when it was shown to be a positive regulator of the Wnt
signaling pathway in yeast two-hybrid screens (Liu et al., 2005; Liu et al., 1998). It was
shown that LRRFJP2 is a positive effector of the canonical Wnt pathway through an
interaction with Disheveled (Dvl). When a Wnt ligand binds to its receptor, Frizzled

(Fz), Dvl is activated and inhibits GSK-3P, releasing kcatenin, which then translocates
to the nucleus and interacts with TCF to function as a transcription factor.
If Fli-I is localized in the nucleus, LRRFIP2 can not interact with Dvl to up
regulate kcatenin mediated transcription. Since Fli-I is extra-nuclear in a manner
proportional to CaMK-I1 activity, Wnt signal transduction would be elevated at times of
high activity. This model suggests that extracellular signaling has regulators inside of the
cell, which would mean that the pathway has increased sensitivity to a variety of stimuli.
In transformed cells CaMK-I1 expression is down regulated (Tombes et al., 1999),
meaning that extracellular signals which are transduced by the canonical Wnt pathway
are not efficiently relayed, which could contribute to the carcinogenic characteristics
exhibited by these cells. This could be a previously undescribed regulatory pathway that
needs to be fi~rthercharacterized.
A number of additional experiments are necessary to more specifically define the
nature of the interaction. They include:
Adding the GFP tag to Fli-I
Fluorescently tagging Fli-I would make it possible to characterize its
movement in living cells and to analyze its kinetics into and out of the
nucleus under different conditions
Colocalizing CaMK-I1 and Fli-I
The localization of Fli-I can be complimented by showing the position of
CaMK-I1 and Fli-I at the same time under the various experinlental
conditions that Fli-I alone was localized during. This could be done by
imaging each protein in different fluorescent channels.

Domain Mapping of the CaMK-11-Fli-I interaction
To further understand the properties of the interaction it is essential to
know where they binding is occurring. This can be done by using deletion
constructs, which create truncated proteins and deterniine which domains
are essential for binding. This could be followed up by using point
mutants to define the required amino acid residues to facilitate binding.
In vitro translation and direct binding assay
Using reticilolysate it is possible to translate proteins in vitro and test for
their interaction. mRNA made from CaMK-I1 and Fli-I could be
translated and the interaction could be confirmed. This would eliminate
any question of whether or not the association of Fli-I and CaMK-I1 is
direct or indirect. There are commercially available kits for this type of
assay which makes this a practical and worthwhile experiment.
Biochemical Characterization of the CaMK-11-Fli-I interaction
Currently nothing is known of the biochen~icalaspects of the interaction
and will need to be defined. This will include studying the kinetics of
the Fli-I translocation, its rate of turnover, the binding affinity of the two
proteins, and identifying which growth factors are essential to keep Fli-I in
the cytosol. These experiments will reveal in greater detail the already
confirmed interactioii and offer insight to its intracellular functions.
Gene expression effected by the CaMK-11-Fli-I interactioii
Using CaMK-I1 inhibitors to minimize its activity and RNAi to lower Fli-I
expression gene expression patterns can be characterized using DNA

microarray analysis. Genes that are down regulated when both CaMK-I1
is inhibited and Fli-I expression is minimized could potentially be
dependent on the interaction.
The effects of CaMK-I1 oil Wnt pathway components
Since it is possible that through its interaction with Fli-I and
LRRFIP2 that CaMK-I1 could be effecting Wnt based transcription it will
be necessary to examine what is happening to components in the pathway.
This can be done immunologically to look at the phosphorylation state of
GSK-3P or for the presence of p-catenin, for example.
Whole organism studies
It is important to also characterize the effects of this interaction in a whole
organism. Since both proteins are developmentally essential a good
system for studying their roles during development would be the zebra
fish, Danio rerio.

These experiments will make if possible to further describe the CaMK-I1 and Fli-I
interaction. This work is the first description of what has the potential to be a new
intracellular regulatory pathway. Both of these proteins are ubiquitously expressed and
highly conserved throughout all metazoans. This is reflective of their cellular importance
and means that their interaction could be quite ancient. The complexity with which each
but is even more intricate when they cooperate. The
is regulated is profo~~nd,
identification of Fli-I and CaMK-I1 by MSIMS is exciting not only because of its cellular
significance but because it is representative of a new class of biochemical approaches

which will make it possible to characterize the cross talk that exists between well
established cellular pathways.

Table 1. MSIMS Results Table. The Names, NCBI protein accession numbers, and total
number of peptides detected of tlie proteins identified as potential CaMK-I1 binding
partners using MS/MS. The total number of peptides is the number of peptides that were
analyzed and analyzed by SEQUEST to determine the legitimacy of the result.
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Figure 1. Linear FLAG/GFP-Cam-II map. The FLAG-tag was h s e d to the N-terminal side
of the GFP tag and is 8 residues long. The GFP-tag is 245 amino acids long and is located on
the N-terminal side of CaMK-11. The catalytic domain of CaMK-IT is just over 250 amino
acids long and is adjacent to the regulatory domains, which is 30 residues in length. The
variable domain differnces in size between isozymes and is where alternative splicing occurs.
The C-terminal most domain is the association domain.

Figure 2. The FLAG elution process eliminates non-specifically boundproteins. Panel A is a
GFP western blot of the FLAG eluents. Lane 1 is the lysate of the transfected cells and lane 2
is the first elution and lane 3 is the second. Panel B is a SYPRO Ruby total protein stain of
the FLAG eluents. The bands at Lane 1 is the lysate of the transfected cells, lane 2 is that first
eluent and lane 3 is the second. In both images the bands at 25 and 50 kDa correspond to the
IgG light and heavy chains and the band at 80 kDa is the M, of FLAG/mGGEWT. It is clear
that the majority of the proteins are cleared from the lysate.

Fli-I

lntegrin
Immunoprecipitating Antibody

Figure 3. Reciprocal IP of endogenous C a m - 1 1 and Fli-I. In panel A, CaMK-I1 antibodies
were used against untreated lystates. Lane 1 is whole cell lysates, lane 2 is a P CaMK-I1
antibody and lane 3 is a 6 CaMK-I1 antibody immunoprecipitation of whole cell lystate. All
three were probed with an anti-Fli-I antibody and show a band in the 145 kDa region,
corresponding to the M, of Fli-I. Panel B shows a Fli-I LP that was probed with biotinylated
CaM. Lane 1 is whole cell lysate and lane 2 is a FIi-I IP. There are multiple bands in the 5460 kDa region, representative of the mass of various CaMK-I1 isozymes. Panel C shows a
graph of the amount of CaMK-I1 activity that was recovered from a Fli-I IP as compared to an
integrin LP, which is known to not bind CaMK-11.

Figure 4. C a m - 1 1 activity dependent association with Fli-I. N M 3T3 cells were
transfecterd with FLAGIGFP-tagged GE CaMK-11. In panel A, lane 1 is nonimmunoprecipitated untransfected lysate to illustrate input, lane 2 is FLAG/mGGEWT,lane 3
is FLAGlmGGECon,lane 4 is FLAG/mGGEWTwith 10 pM kn-93, and lane 5 is
FLAG/mGGEWTwith 10 pM mAIP. Lanes 2-5 were immunprecipitated using an anti-GFP
antibody then western blotted for Fli-I. Lane 3, has more Fli-I associated then does the
control, lane 2 and much more than the lanes 4 and 5, the CaMK-I1 inhibited samples. The
relative amounts of CaMK-I1 expressed in the samples as determined enzymatically are
represented in panel B. It is intersting to note that the KN-93 and mAIP treated samples are
expressed at a much higher level, but had much less Fli-I and F L A G / ~ G G E Cwas
O ~ the
lowest and had the most Fli-I bound. Panel C shows the CaMK-I1 autonomy of the samples
and illustrates that greater autonomy, which corresponds to greater quantity of Fli-I

Figure 5. Fli-Ilocalization in NIH 3T3 cells. Fli-I can be specifically visualized in NIH 3T3
cells using Texas Red conjugated anitbodies. Fli-I is a very dynamic molecule that localizes
in a variety of patterns that are correlated to the cell's activities. It can be entirely in the
cytosol in cells that are motile and active (panel A). Fli-I can also assume a heterogenous
localization pattern, both in and out of the nucleus, in a single culture (panel B). It can also
be primarily nuclear, which is suggestive of cell arrest (panel C). Scale bar represents 50 pm.

Figure 6. Fli-I localizes to the nucleus in arrested cells. During times of activity Fli-I is
found outside of the nucleus and associating with actin based structures (panel A). When
cells arrest is induced with serum starvation, Fli-I begins to translocate to nucleus and can be
visualized there within 6 hours (panel B). Twelve hours after serum starvation, the majority
of Fli-I is in the nucleus and that which remains in the nucleus is nonspecifically localized
(panel C). If arrect is induced by contact, N M 3T3 cells arrest. Cells at a high density have
Fli-I localized to the nucleus and cytosolically in an undefined manner (panel D). Scale bar
represents 50 pm.

Figure 7. Fli-I exits the nucleus in serum stimulated cells. Fli-I is sequestered in the nucleus
of serum starved cells (panel A). If these cells are stimulated with serum containing medium,
FIi-I can begin to be seen localizing along actin based structures in the cytosol within 6 hours
(panel b). Twelve hours after stimulation, Fli-I can still be visualized in the nucleus, but at a
lower instensity and more dynamically in the cytosol (panel C). Eighteen hours after serum
has been added to the culture all of the Fli-I has translocated to the cytosol and is associated
with actin structures and alond the cell edges (panel D). Scale bar represents 50 pm.

Figure 8. KN-93 causes Fli-Ito translocate to the nucleus. NIH 3T3 cells that are active
exhibit cytosolic Fli-I localization patters (panel A). If these cells are treated with 10 pM
KN-93, Fli-I begins to be transported into the nucleus and can be seen there within 4 hours of
treatment (panel B). Twelve hours after KN-93 is added to the culture the majority of Fli-I is
localized to the nucleus, though some remains outside the nucleus, but is less specifically
localized (panel C). Eighteen hours post-treatment Fli-I is sequestered to the nucleus (panel
D). Scale bar represents 50 pm.

Figure 9. Fli-I is sequestered to the nucleus by mAIP CaMK-TI Inhibition. In a manner very
similar to treatment with KN-93, 10
mAlP causes Fli-I to translocate to the nuclues. It
associates with various structures in the cytosol in active cells (panel A). 90 minutes after
active cells are treated with mAIP much of the cell's Fli-I has moved into the nucleus (panel
B). Three hours after the mAIP treatment, Fli-I has become sequestered in the cell's nucleus
(panel C). Scale bar represents 50 p.m.

Figure 10. Fli-I is not sequestered to the nucleus in arrested cells when CaMK-II artzficially
activated. In serum free conditions FIi-I is sequestered to the nucleus. It is possible to
reverse this localization by treating cells with the ca2+ionophore ionomycin which artifically
activates CaMK-11. Prior to treatment with ionomycin, FIi-I is localized in the nucleus in
serum free conditions (Panel A). When the culture is treated with ionomycin for 12 hours, a
cytosolic presence of Fli-I can begin to be seen (Panel B). 18 hours after the treatment with
ionomycin all of the cell's Fli-I in the cytosol and is in the regions where it is found in the
cell's cytosol even though the cells are arrested (Panel C).

Figure I I . Potential Model of CaMK-II and Fli-IS interaction. A potential graphical
representation of the CaMK-11-Fli-I interaction. When ca2' rises in the cell, it becomes
bound by the ca2+binding protein CaM. c a 2 ' / c a ~is bound by CaMK-11 and becomes
catalytically active. In its active state CaMK-11 is capable of binding Fli-I, which is otherwise
sequestered to the nucleus. When Fli-I exits the nucleus and CaMK-I1 is active they associate
and travel to actin filaments throughout the cell and at its edges.
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